These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 36399377)

  • 41. Escape of Hepatitis C Virus from Epitope I Neutralization Increases Sensitivity of Other Neutralization Epitopes.
    Gu J; Hardy J; Boo I; Vietheer P; McCaffrey K; Alhammad Y; Chopra A; Gaudieri S; Poumbourios P; Coulibaly F; Drummer HE
    J Virol; 2018 May; 92(9):. PubMed ID: 29467319
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies.
    Vietheer PT; Boo I; Drummer HE; Netter HJ
    Antivir Ther; 2007; 12(4):477-87. PubMed ID: 17668556
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Multiplex flow cytometry-based assay to study the breadth of antibody responses against E1E2 glycoproteins of hepatitis C virus.
    Merat SJ; van de Berg D; Bru C; Yasuda E; Breij E; Kootstra N; Prins M; Molenkamp R; Bakker AQ; de Jong MD; Spits H; Schinkel J; Beaumont T
    J Immunol Methods; 2018 Mar; 454():15-26. PubMed ID: 28855105
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Broad neutralization of hepatitis C virus-resistant variants by Civacir hepatitis C immunoglobulin.
    Tawar RG; Heydmann L; Bach C; Schüttrumpf J; Chavan S; King BJ; McClure CP; Ball JK; Pessaux P; Habersetzer F; Bartenschlager R; Zeisel MB; Baumert TF
    Hepatology; 2016 Nov; 64(5):1495-1506. PubMed ID: 27531416
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High-density lipoproteins reduce the neutralizing effect of hepatitis C virus (HCV)-infected patient antibodies by promoting HCV entry.
    Voisset C; de Beeck AO; Horellou P; Dreux M; Gustot T; Duverlie G; Cosset FL; Vu-Dac N; Dubuisson J
    J Gen Virol; 2006 Sep; 87(Pt 9):2577-2581. PubMed ID: 16894196
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein.
    Helle F; Goffard A; Morel V; Duverlie G; McKeating J; Keck ZY; Foung S; Penin F; Dubuisson J; Voisset C
    J Virol; 2007 Aug; 81(15):8101-11. PubMed ID: 17522218
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Study of neutralization antibodie induced by DNA vaccine of HCV envelope protein 2 in mice].
    Shao S; Zhou H; Tong Y; Ren Y; Chen Z
    Wei Sheng Yan Jiu; 2011 May; 40(3):295-8. PubMed ID: 21695897
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Extra-epitopic hepatitis C virus polymorphisms confer resistance to broadly neutralizing antibodies by modulating binding to scavenger receptor B1.
    El-Diwany R; Cohen VJ; Mankowski MC; Wasilewski LN; Brady JK; Snider AE; Osburn WO; Murrell B; Ray SC; Bailey JR
    PLoS Pathog; 2017 Feb; 13(2):e1006235. PubMed ID: 28235087
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neutralizing antibodies induced by cell culture-derived hepatitis C virus protect against infection in mice.
    Akazawa D; Moriyama M; Yokokawa H; Omi N; Watanabe N; Date T; Morikawa K; Aizaki H; Ishii K; Kato T; Mochizuki H; Nakamura N; Wakita T
    Gastroenterology; 2013 Aug; 145(2):447-55.e1-4. PubMed ID: 23673355
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Oral immunization with attenuated Salmonella carrying a co-expression plasmid encoding the core and E2 proteins of hepatitis C virus capable of inducing cellular immune responses and neutralizing antibodies in mice.
    Cao J; Chen Z; Ren Y; Luo Y; Cao M; Lu W; Zhao P; Qi Z
    Vaccine; 2011 May; 29(20):3714-23. PubMed ID: 21396407
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Expression, purification and immunogenic characterization of hepatitis C virus recombinant E1E2 protein expressed by Pichia pastoris yeast.
    Cai W; Su L; Liao Q; Ye L; Wu Y; Wu Z; She Y
    Antiviral Res; 2010 Oct; 88(1):80-5. PubMed ID: 20691736
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Neutralizing antibody response to hepatitis C virus.
    Wang Y; Keck ZY; Foung SK
    Viruses; 2011 Nov; 3(11):2127-45. PubMed ID: 22163337
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neutralizing activities of caprine antibodies towards conserved regions of the HCV envelope glycoprotein E2.
    El Abd YS; Tabll AA; El Din NG; Hosny Ael-D; Moustafa RI; El-Shenawy R; Atef K; El-Awady MK
    Virol J; 2011 Aug; 8():391. PubMed ID: 21819575
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inactivated whole hepatitis C virus vaccine employing a licensed adjuvant elicits cross-genotype neutralizing antibodies in mice.
    Pihl AF; Feng S; Offersgaard A; Alzua GP; Augestad EH; Mathiesen CK; Jensen TB; Krarup H; Law M; Prentoe J; Christensen JP; Bukh J; Gottwein JM
    J Hepatol; 2022 May; 76(5):1051-1061. PubMed ID: 34990750
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Naturally selected hepatitis C virus polymorphisms confer broad neutralizing antibody resistance.
    Bailey JR; Wasilewski LN; Snider AE; El-Diwany R; Osburn WO; Keck Z; Foung SK; Ray SC
    J Clin Invest; 2015 Jan; 125(1):437-47. PubMed ID: 25500884
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Conformational Flexibility in the Immunoglobulin-Like Domain of the Hepatitis C Virus Glycoprotein E2.
    Vasiliauskaite I; Owsianka A; England P; Khan AG; Cole S; Bankwitz D; Foung SKH; Pietschmann T; Marcotrigiano J; Rey FA; Patel AH; Krey T
    mBio; 2017 May; 8(3):. PubMed ID: 28512091
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anti-envelope antibody responses in individuals at high risk of hepatitis C virus who resist infection.
    Swann RE; Mandalou P; Robinson MW; Ow MM; Foung SK; McLauchlan J; Patel AH; Cramp ME
    J Viral Hepat; 2016 Nov; 23(11):873-880. PubMed ID: 27405885
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus.
    Giang E; Dorner M; Prentoe JC; Dreux M; Evans MJ; Bukh J; Rice CM; Ploss A; Burton DR; Law M
    Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6205-10. PubMed ID: 22492964
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Design of a native-like secreted form of the hepatitis C virus E1E2 heterodimer.
    Guest JD; Wang R; Elkholy KH; Chagas A; Chao KL; Cleveland TE; Kim YC; Keck ZY; Marin A; Yunus AS; Mariuzza RA; Andrianov AK; Toth EA; Foung SKH; Pierce BG; Fuerst TR
    Proc Natl Acad Sci U S A; 2021 Jan; 118(3):. PubMed ID: 33431677
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vivo evaluation of the cross-genotype neutralizing activity of polyclonal antibodies against hepatitis C virus.
    Meuleman P; Bukh J; Verhoye L; Farhoudi A; Vanwolleghem T; Wang RY; Desombere I; Alter H; Purcell RH; Leroux-Roels G
    Hepatology; 2011 Mar; 53(3):755-62. PubMed ID: 21319203
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.